---
title: Myvelpa
image: "/uploads/01-myvelpa.jpg"
group: Hepatitis C
ingredient: Sofosbuvir, Velpatasvir
excipients: |-
  Drug Excipients: Copovidone, Lactose Monohydrate, Microcrystalline Sodium (Ceolus UF
  702), Microcrystalline Cellulose (Avicel PH 112), Croscarmellose Sodium, Colloidal Silicon
  Dioxide, Magnesium Stearate
  Coating Systems Excipients (Green TC-510031): Polyvinyl Alcohol, Polyethylene Glycol,
  Titanium Dioxide, Talc, Indigo carmine Aluminum lake, Iron Oxide Yellow
assign: Velpatasvir/sofosbuvir tablets are indicated for the treatment of chronic
  hepatitis C virus infection in adults.
expiry_date: 24 moths
pack: Bottle of 28 tablets
preservation: |-
  Drugs are to be stored in a cool and dry place, below 30Â°C. Store in original packaging.
  Keep out of reach of children.
  Read the user manual carefully before use.
origin: India
amount_use: Take 1 tablet (400mg sofosbuvir/100mg velpatasvir) daily, with or without
  food.
contraindications: Patients with hypersensitivity to the components of the drug and
  pregnant women.
careful: |-
  - Do not use velpatasvir/sofosbuvir tablets concurrently with other medicinal products containing sofosbuvir.
  - Bradycardia and severe heart block.
  - The patient has failed a treatment regimen containing NS5A.
  - Patients with kidney failure.
  - The patient is taking moderate P-gp and CYP inducers.
  - Use in combination with HIV treatment regimens.
  - Patients are coinfected with HCV and HBV (hepatitis B).
  - Patients with cirrhosis of the liver CPT index C.
  - Liver transplant patient.

---
